Posted inLatest news

Janus Henderson launches Horizon Biotechnology Fund

Janus Henderson Investors has launched launch of the Janus Henderson Horizon Biotechnology Fund.

The Luxembourg-domiciled Sicav will invest in “innovative biotechnology and biotechnology-related companies that seek to address high unmet medical needs around the world,” the group said. “The fund will target long-term growth within this fast growing and innovative sector.”

The fund will be co-managed by Andy Acker and Dan Lyons, who have more than 40 years of combined experience investing in biotechnology.

Ignacio de la Maza, Head of Continental Europe, Wholesale & Latin America said: ‘We are launching the fund to meet the needs of those clients searching for additional opportunities to invest in biotechnology. The fund will be managed by a team of experts with extensive scientific backgrounds and supported by the larger Janus Henderson healthcare investment team.’

Andy Acker noted: “The pace of progress in the biotechnology industry is accelerating, leading to more rapid medical breakthroughs. So far in 2018, the FDA has approved 55 new therapies – an all-time record.”

Dan Lyons added: “Our process focuses on the scientific and business drivers that are critical to mitigating the risks and uncovering the opportunities presented by this dynamic sector.”

David Robinson

David Robinson is the editor of Expert Investor. He has 18 years’ experience as a business journalist and editor. In the past he has written for the Guardian newspaper and The Telegraph, and worked as...

Part of the Bonhill Group.